Gene therapy

Cell and gene therapies
#Diabetes #Fractyl Health #Gene therapy #GLP-1 #Phase I trial

First GLP-1 gene therapy gets green light for diabetes trial

Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the company’s Rejuva Smart GLP-1 gene therapy platform.   With this authorisation, Fractyl believes RJVA-001 is the first adeno-associated virus (AAV)-based gene therapy… Read More

#News #Trending News

#CNS #Financing #Gene therapy #Latus Bio

Latus Bio announces $97 million series A financing

Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline.   The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund.   Korea Development Bank… Read More

#Business & Investment #News

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

eBook: Where next for cell & gene therapy?

Cell and gene therapies (CGT) have been transformative for the treatment several diseases, particularly haematological cancers and genetic conditions like sickle cell disease, with many new indications in the pipeline. This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment,… Read More

#News

DDW CGT eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Where next for cell & gene therapy?

This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment, and the challenges and opportunities of a changing regulatory landscape.

#DDW eBooks #Intelligence

Gene therapy
#FDA #Gene therapy #Hearing Loss #Regeneron Pharmaceuticals

FDA approves first gene therapy for genetic hearing loss

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment of paediatric and… Read More

#News #Regulatory #Trending News

MRI showing glioblastoma
#Brain cancer #Gene therapy #Trogenix

Gene therapy could eradicate tumours in brain cancer 

An innovative gene therapy could achieve complete tumour elimination in brain cancer, data shows.  Biotechnology company Trogenix has announced the publication of breakthrough preclinical data, reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM).  The results, published in … Read More

#Cancer Research #News

Cell and gene therapy
#FDA #Gene therapy #Paediatrics #Rare disease #Rocket Pharmaceuticals

First gene therapy for rare paediatric disease gets US approval

The US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy.  It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling… Read More

#News #Regulatory #Trending News

Gene therapy
#Advanced Therapies #Atamyo Therapeutics #Gene therapy #Muscular dystrophy

Gene therapy for limb-girdle muscular dystrophy shows promise

Atamyo Therapeutics has shared the first clinical results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy associated with γ-sarcoglycan deficiency (SGCG, gamma-sarcoglycanopathy).   The results are from a Phase Ib/II clinical trial conducted at the Powell Gene Therapy Center at the University of Florida, supported by… Read More

#Editor's Choice #News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

#DNA technology #Gene synthesis #Gene therapy #Protein design

Cell-free DNA programme could ‘empower’ therapeutics to market

A newly accessible cell-free DNA programme could “empower” therapeutics to market, the CEO of Ribbon Bio has said. Jodi Barrientos, CEO of the synthetic biology company, was speaking at the ‘Engineering Biology: DNA and Beyond’ conference in Vienna, Austria, which took place on the 5 and 6 March. At the… Read More

#News

#Advanced Therapies #FDA #Gene therapy #Huntington's disease #uniQure

Investors file lawsuit against uniQure following FDA ruling

The US Food and Drug Administration (FDA) has ruled that data from Phase I/II studies are insufficient evidence to approve the marketing authorisation for uniQure’s AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In response, investors have issued a class action securities lawsuit to recover losses.  The FDA said… Read More

#Business & Investment #News #Trending News

CRISPR gene editing
#Advanced Therapies #FDA #Gene therapy #Intellia Therapeutics #Phase III trial

Regulator lifts clinical hold on Intellia’s gene therapy trials

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase III clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).  The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed… Read More

#News #Regulatory #Trending News

Gene editing
#Advanced Therapies #Fast Track designation #FDA #Gene editing #Gene therapy #Tessera Therapeutics

In vivo gene editing programme for AATD fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, Tessera Therapeutics’ lead in vivo gene editing programme.  TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ).  … Read More

#Editor's Choice #News #Regulatory

#Atsena Therapeutics #Clinical research #Gene therapy #Ocular diseases

Navigating academia and industry to deliver ocular gene therapies

Dr Shannon E Boye, Co-Founder and Chief Scientific Officer of Atsena Therapeutics, writes about the company's journey to the clinic for a challenging ocular gene therapy target.   I have worked for nearly 20 years across academia and the biopharmaceutical industry to develop gene therapies for inherited retinal diseases. I met Sanford Boye, my other half in life and in science, in the lab. If you name… Read More

#Exclusive Content